Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a sensory room soothe Dementia's agitation and anxiety?

NCT ID NCT07657208

Symptom relief Sponsor: University of Primorska Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This study tests whether Snoezelen multisensory therapy — a calming, personalized experience using lights, sounds, textures, and scents — can reduce agitation, depression, and anxiety in older adults with dementia. Sixty participants with mild to moderate dementia will receive either standard care or standard care plus three 30-minute Snoezelen sessions per week for 12 weeks. Researchers will measure changes in mood, behavior, heart rate, and stress hormones to see if this drug-free approach improves well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Snoezelen Multisensory Therapy
What this could lead to
If effective, this drug-free therapy could offer a way to ease distressing symptoms like agitation and depression in people with dementia.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply widely. The therapy may provide only temporary relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

63 people

The number who actually took part.

Started

Aug 2023

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 65 years or older Diagnosed dementia (any subtype) Montreal Cognitive Assessment (MoCA) score between 10-25 Mini Mental State Examination (MMSE) between 10-24 Behavioral and psychological symptoms of dementia (BPSD), indicated by at least one of the following: Cornell Scale for Depression in Dementia (CSDD) score \>10 Hospital Anxiety and Depression Scale (HADS) score \>8 Cohen-Mansfield Agitation Inventory (CMAI) showing moderate or severe symptoms Ability to follow basic instructions and communicate needs Written informed consent obtained from the participant or their legal representative Exclusion Criteria: * Acute psychiatric illness or unstable somatic condition Severe visual or hearing impairments Inability to communicate in Slovenian Concurrent participation in psychotherapy or physiotherapy Diagnosis of epilepsy Changes to psychiatric medication within 4 weeks prior to study start Any other condition that, in the opinion of the research team, would interfere with participation or data collectio

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior Cognitive Dysfunction dementia Depression Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia

Contacts and locations

Locations

  • Center for Older Adults Lucija

    Portorož, 6320, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.